Pyroglutamylated RFamide Peptide (Human)

Code:
4419-s
Name:
Pyroglutamylated RFamide Peptide (Human)
QRFP (Human)
Pyr-Asp-Glu-Gly-Ser-Glu-Ala-Thr-Gly-Phe-Leu-Pro-Ala-Ala-Gly-Glu-Lys-Thr-Ser-Gly-Pro-Leu-Gly-Asn-Leu-Ala-Glu-Glu-Leu-Asn-Gly-Tyr-Ser-Arg-Lys-Lys-Gly-Gly-Phe-Ser-Phe-Arg-Phe-NH2
(M.W. 4503.8) C199H301N55O65
Endogenous Ligand for AQ27 / SP9155 / GPR103
Package Price(Yen) Availability Quantity  
Vial 0.1 mg 13,000 Ships within
1-3 business days
バルク見積もり

main

Purity:
≧99.0% (HPLC)
Storage:
-20 ℃
Production:
Synthetic Product

Solubility: H2O (0.1 mM)

more information

Category:
Biologically Active Peptides

reference

  1. S. Fukusumi, H. Yoshida, R. Fujii, M. Maruyama, H. Komatsu, Y. Habata, Y. Shintani, S. Hinuma, and M. Fujino, J. Biol. Chem., 278, 46387 (2003). (Original)
  2. Y. Jiang, L. Luo, E.L. Gustafson, D. Yadav, M. Laverty, N. Murgolo, G. Vassileva, M. Zeng, T.M. Laz, J. Behan, P. Qiu, L. Wang, S. Wang, M. Bayne, J. Greene, F. Monsma, Jr., and F.L. Zhang, J. Biol. Chem., 278, 27652 (2003). (Orphan Receptor Ligand / 26-Residue Peptide, P518)
  3. N. Chartrel, C. Dujardin, Y. Anouar, J. Leprince, A. Decker, S. Clerens, J.-C. Do-Réo, F. Vandesande, C. Llorens-Cortes, J. Costentin, J.-C. Beauvillain, and H. Vaudry, Proc. Natl. Acad. Sci. U.S.A., 100, 15247 (2003). (26-Residue Peptide, 26RFa)
  4. S. Takayasu, T. Sakurai, S. Iwasaki, H. Teranishi, A. Yamanaka, S.C. Williams, H. Iguchi, Y.I. Kawasawa, Y. Ikeda, I. Sakakibara, K. Ohno, R.X. Ioka, S. Murakami, N. Dohmae, J. Xie, T. Suda, T. Motoike, T. Ohuchi, M. Yanagisawa, and J. Sakai, Proc. Natl. Acad. Sci. U.S.A., 103, 7438 (2006). (Pharmacol.)
  5. R. Moriya, H. Sano, T. Umeda, M. Ito, Y. Takahashi, M. Matsuda, A. Ishihara, A. Kanatani, and H. Iwaasa, Endocrinology, 147, 2916 (2006). (Pharmacol.)
  6. S. Fukusumi, R. Fujii, and S. Hinuma, Peptides, 27, 1073 (2006). (Review)
  7. D.A. Bechtold and S.M. Luckman, J. Endocrinol., 192, 3 (2007). (Review)

関連書類

PDF SDS: Japanese / English

他の製品を検索する
商品へのこだわり
当社の技術


Scroll to top